Insulet (PODD) – Investment Analysts’ Weekly Ratings Changes

Insulet (NASDAQ: PODD) has recently received a number of price target changes and ratings updates:

• 5/13/2025 – Insulet was upgraded by analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating. They now have a $350.00 price target on the stock.
• 5/9/2025 – Insulet had its price target raised by analysts at Oppenheimer Holdings Inc. from $312.00 to $324.00. They now have an “outperform” rating on the stock.
• 4/30/2025 – Insulet had its price target raised by analysts at Barclays PLC from $234.00 to $266.00. They now have an “equal weight” rating on the stock.
• 4/29/2025 – Insulet was downgraded by analysts at Wolfe Research from an “outperform” rating to a “peer perform” rating.
• 4/28/2025 – Insulet was given a new $322.00 price target on by analysts at Wells Fargo & Company.

Insulet Price Performance

Shares of PODD stock opened at $322.02 on Friday. Insulet Co. has a 1 year low of $170.67 and a 1 year high of $323.00. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The firm’s 50 day moving average is $262.55 and its 200-day moving average is $265.81. The firm has a market capitalization of $22.66 billion, a price-to-earnings ratio of 55.62, a PEG ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.21. The firm had revenue of $569.00 million for the quarter, compared to the consensus estimate of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.73 EPS. Sell-side analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president now directly owns 23,180 shares in the company, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.

Institutional Trading of Insulet

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after acquiring an additional 178,976 shares in the last quarter. Baillie Gifford & Co. increased its stake in Insulet by 3.5% during the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock worth $614,998,000 after purchasing an additional 79,982 shares in the last quarter. Geode Capital Management LLC raised its holdings in Insulet by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier’s stock worth $463,347,000 after buying an additional 40,566 shares during the period. American Century Companies Inc. lifted its stake in Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock valued at $302,686,000 after buying an additional 297,734 shares in the last quarter. Finally, Groupama Asset Managment boosted its holdings in shares of Insulet by 0.4% in the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock valued at $276,728,000 after buying an additional 3,759 shares during the period.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.